Cablivi for Acquired Thrombotic Thrombocytopenic purpura

The 2 corporations formed the Bristol Myers Squibb-Pfizer Alliance and will be offering discounted Eliquis to eligible patients starting September 8, 2025.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

The Cut Hypertension Program operates in barbershops across the Bay Area in California. The program’s lead pharmacist joined us to discuss main themes and goals of the new initiative.

Patients with a single cardiometabolic disease have an approximate 48% greater risk of developing all-cause dementia compared with those without a cardiometabolic disease.

The therapy is now the first and only oral on demand treatment option for the condition.